Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment
- Conditions
- Interventions
- First Posted Date
- 2020-02-27
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 18
- Registration Number
- NCT04287894
- Locations
- 🇳🇱
Antoni van Leeuwenhoek - Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands
Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2021-10-27
- Lead Sponsor
- Emory University
- Registration Number
- NCT04262869
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- Conditions
- Interventions
- Drug: PembrolizumabDrug: CarboplatinDrug: PaclitaxelDrug: Nab paclitaxelOther: Quality of Life Questionnaire, lung cancer-specific (QLQ-LC13)Other: QLQ-C30 Global Health/Quality of Life QuestionnaireOther: COPD Assessment Test and modified Medical Research Council Dyspnea Patient Reported OutcomesDrug: Pemetrexed
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 80
- Registration Number
- NCT04253964
- Locations
- 🇺🇸
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-01-28
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 95
- Registration Number
- NCT04245085
- Locations
- 🇩🇪
LungenClinic Grosshansdorf, Großhansdorf, Germany
🇨🇭Kantonsspital St. Gallen, St. Gallen, Switzerland
🇨🇭UniversitätsSpital Zürich, Zürich, Switzerland
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2020-01-10
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 223
- Registration Number
- NCT04222972
- Locations
- 🇺🇸
UC Irvine Medical Center, Orange, California, United States
🇺🇸Southern California Kaiser Permanente, San Diego, California, United States
🇦🇷Hospital Britanico; Oncologia, Buenos Aires, Argentina
Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma
- Conditions
- Interventions
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Jose Carrillo
- Registration Number
- NCT04220892
- Locations
- 🇺🇸
John Wayne Cancer Institute, Santa Monica, California, United States
Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLC
- Conditions
- Interventions
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2022-11-16
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 45
- Registration Number
- NCT04211090
- Locations
- 🇨🇳
Li-Kun Chen, Guangzhou, Guangzhou, China
Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer
- First Posted Date
- 2019-12-19
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 583
- Registration Number
- NCT04205812
- Locations
- 🇹🇷
Trakya Universitesi Tip Fakultesi, Edirne, Turkey
🇿🇦Wits Clinical Research, Johannesburg, South Africa
🇺🇦Kherson Regional Oncologic Dispensary, Kherson, Ukraine
INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)
- First Posted Date
- 2019-12-18
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT04203511
A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)
- Conditions
- Interventions
- First Posted Date
- 2019-12-11
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 305
- Registration Number
- NCT04194203
- Locations
- 🇨🇳
Guangxi Cancer Hospital of Guangxi Medical University, Nanning City, China
🇨🇳First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, China
🇨🇳Nan Tong Tumor Hospital, Nantong City, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.